Phase II study of erlotinib (Tarceva) combined with chemoradiation and adjuvant chemotherapy in patients with resectable pancreatic cancer.
Phase of Trial: Phase II
Latest Information Update: 27 Jan 2016
At a glance
- Drugs Erlotinib (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Pharmacodynamics; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 05 Nov 2006 New trial record.